Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis

Ratnakar Singh(University of Illinois Urbana-Champaign), Faye M. Johnson(The University of Texas MD Anderson Cancer Center), Bingliang Fang(The University of Texas MD Anderson Cancer Center), Vaishnavi Sambandam(National Comprehensive Cancer Network), Xiayu Rao(The University of Texas MD Anderson Cancer Center), Jing Wang(The University of Texas MD Anderson Cancer Center), Li Shen(The University of Texas MD Anderson Cancer Center), Shaohua Peng(The University of Texas MD Anderson Cancer Center), Pavitra Viswanath(The University of Texas MD Anderson Cancer Center)
EMBO Molecular Medicine
April 30, 2019
10.15252/emmm.201809960
Cited by 28

Related Papers

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
|Cancer Discovery|2023|181
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates
|Nature Communications|2016|159
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
|Oncotarget|2015|147
Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase–STAT3 Binding
|Cancer Research|2009|131